Moxifloxacin-Associated Drug Hypersensitivity Syndrome With Toxic Epidermal Necrolysis and Fulminant Hepatic Failure

Comparative safety profile of levofloxacin versus moxifloxacin in first-line tuberculosis therapy: a pharmacovigilance study of the FAERS database

“…Moxifloxacin undergoes glucuronidation (mediated by UGT1A1/1A3) and biliary excretion, bypassing renal clearance ( Annisa et al, 2022 ). These findings are consistent with clinical observations ( Nori et al, 2004 ; Verma et al, 2009 ). These results underscore the importance of baseline liver function assessment and tailored monitoring strategies in drug-susceptible tuberculosis treatment, especially in high-risk populations with predisposing factors for liver injury.…”

Recurrent Drug-Induced Liver Injury (DILI) with different drugs in the Spanish Registry: The dilemma of the relationship to autoimmune hepatitis

“…This is consistent with recent evidence that links older age to the risk of developing cholestatic injury during hepatotoxicity regardless of the implicated drug [11,26], and in spite of the fact that moxifloxacin-related liver injury, unlike amoxicillin-clavulanate [11], is reported to be hepatocellular [27]. In this case, DILI occurred in an elderly patient and was manifested as cholestatic damage in both episodes.…”

Fluoroquinolones Reported Hepatotoxicity

“…Scan revealed mild splenomegaly [49]. This agreed with the findings of Nori et al (2004) [50] who documented a case of fulminant hepatic failure characterized by elevated liver enzymes in a patient treated with moxifloxacin. Similar observations were also reported by some researchers [51].…”